Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients with relapsed/refractory multiple myeloma (RRMM), according to a study published in The Lancet Haematology.1 Carfilzomib twice weekly is currently approved for the treatment of RRMM but is associated with significant burden to both patients and caregivers as treatment...Continue Reading
CHICAGO (Reuters) – Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. Nick Leschly, CEO of bluebird, speaks in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer The treatment, called...Continue Reading
CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. The treatment, called bb2121, belongs to a hot new therapy class called CAR-T that harvests a patient’s own disease-fighting T-cells, genetically modifies them in...Continue Reading
When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine the most effective treatment method, according to Jeffrey Wolf, M.D. While many physicians in the oncology space have shortened the disease’s name by simply saying “myeloma”, Wolf – who is a clinical...Continue Reading
Issue 26 of Multiple Myeloma Research Review. Highlights include: Selinexor in relapsed/refractory multiple myeloma HIV antivirals overcome carfilzomib resistance in multiple myeloma Outcome and survival trends in multiple myeloma during 2008-2015 Bortezomib before and after high-dose therapy in multiple myeloma Download hereContinue Reading
CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Dr Rob Weinkove spoke at our patient seminar on CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment. Watch the seminar here:Continue Reading
A Kiwi dad who’s dying of lung cancer has been bypassing the Pharmac system to get cheap pharmaceuticals directly from India – and says thousands of other patients could do the same. Baden Ngan Kee was diagnosed with terminal lung cancer – despite having never smoked – in 2016. By October last year the cancer...Continue Reading
ANZMAP Multiple Myeloma Highlights from ASH 2017 This publication provides summaries of key clinically relevant multiple myeloma data presented at the 59th ASH Annual Meeting and Exposition, 9–12 December 2017 in Atlanta, Georgia, USA. The Chair (Associate Professor Peter Mollee) and clinicians involved in the Australian and New Zealand Myeloma Ambassador Program (ANZMAP) selected the...Continue Reading
